Five Prime Announces Third Quarter 2016 Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
Five Prime Therapeutics (FPRX) Misses Q3 EPS by 21c
November 4, 2016 8:12 AM EDTFive Prime Therapeutics (NASDAQ: FPRX) reported Q3 EPS of ($0.72), $0.21 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $6.7 million versus the consensus estimate of $7.5 million.
Five Prime continues to expect full-year 2016 net cash used in operating activities to be less... More
